Mediquo Opens its Capital to Mexican Company Silanes to Make the Leap into the Country

Mediquo continues its expansion in Latin America and lands in Mexico. The Barcelona-based telemedicine company has closed a $1.02 million (€1 million) financing round, according to Guillem Serra, CEO of the company.

The deal has been led by Laboratorios Silanes, a Mexican pharmaceutical company that also has an international presence. The round is divided into two phases and aims to underpin Mediquo’s expansion in the Latin American market.

Through a communication platform specialized in instant messaging, both in-app and web versions, Mediquo provides a medical care service by chat, call, or video call to both companies and individuals. The company also has a B2B business line.

Read more about Mediquo and its plans to enter the Mexican market with our companion app. The Born2Invest mobile app keeps its readers up to date with the latest financial news in the world.

Mediquo closed an agreement with Algar Telecom to enter Brazil in November 2021

Last November, the Spanish company closed another agreement with the Brazilian Algar Telecom to offer its service in Brazil. However, the latter company did not become part of Mediquo’s capital. The Spanish company, which was born in 2013 by the hand of Serra, closed its fourth financing round, for $2.34 million (€2.3 million), in April 2021.

Most of the company’s existing partners participated in this round, in addition to Encomenda Smart Capital, the fund led by Carlos Blanco, and the investment platform Dozen Investments, formerly The Crowd Angel.

The first operation of this kind carried out by the Spanish company was closed in 2018, when it raised €3 million. In this case, the economic injection was led by Leandro Sigman, president of Insud Pharma, a multinational pharmaceutical company present in forty of countries.

Silanes is present in the United States, Latin America, the European Union, Africa and Asia Laboratorios

Silanes has focused on research and development (R&D) and has more than 150 patents. The company is present in the United States and several countries in Latin America, the European Union, Africa, and Asia.

The Mexican company specializes in various areas such as diabetes, cardiovascular health, acute and chronic pain, the central nervous system, and nutrition. It also has an antivenom research and production unit.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.